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Abstract
Objective
Tissue destruction in rheumatoid arthritis (RA) is predominantly mediated by matrix metal-
loproteinases (MMPs), thereby generating protein fragments. Previous studies have
revealed that these fragments include MMP-mediated collagen type I, II, and III degrada-
tion, citrullinated and MMP-degraded vimentin and MMP degraded C-reactive protein. We
evaluated if biomarkers measuring serum levels of specific sequences of the mentioned
fragments would provide further information of diagnostic and/or prognostic processes in
early arthritis.
Methods
Ninety-two early arthritis patients (arthritis duration<1 year, DMARD naïve) were enrolled.
Patients either fulfilled the ACR/EULAR2010 criteria for RA (n = 60) or had unclassified
arthritis (UA) (n = 32). Patients fulfilling the RA criteria after 2 years follow-up were classified
into non-erosive (n = 25), or erosive disease (n = 13). Concentrations of the biomarkers:
C1M, C2M, C3M, VICM and CRPM were measured in baseline serum.
Results
C1M, C3M and CRPM were able to discriminate between the UA and RA baseline diagno-
sis in 92 patients with an AUROC of 0.64 (95%CI 0.517 to 0.762), 0.73 (95%CI 0.622 to
0.838) and 0.68 (95%CI 0.570 to 0.795). C2M showed a potential for discrimination
between non-erosive and erosive disease in 38 patients with an AUROC of 0.75 (95%CI
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0.597 to 0.910). All of the applied biomarkers correlated with one or more of the disease
activity parameters: DAS28, ESR, CRP, SJC66, TJC68 and/or HAQ.
Conclusion
This is the first study evaluating the applied biomarkers at this early stage of arthritis. C1M,
C3M, CRPMmight be the best diagnostic marker, whereas high levels of C2M indicated
progression of disease at follow-up in early RA patients.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease of unknown etiology, character-
ized by synovial inflammation in multiple joints [1]. Moreover, RA is associated with excessive
turnover of connective tissues of the joints, specifically the extracellular matrix (ECM) in carti-
lage, bone and synovium. Consequently joints become damaged and disabled [2,3].
Throughout the last 25 years several treatment regimens have been developed, but none of
them are effective in all patients [4,5]. It is therefore of interest to subclassify patients for fur-
ther characterization of the pathogenesis of the disease, which may lead to a better understand-
ing of the disease [6,7]. Early detection of joint damage may be identified and characterized by
biochemical markers that predict which patients have severe ongoing joint damage and hence
are in need of most aggressive treatment [8,9].
The ECM of the cartilage consists mainly of type II collagen, while type I and III collagens
are the main proteins of soft tissue surrounding the joint, as the synovium and entheses [10].
Examining the turnover of these and other collagens may aid the understanding of RA patho-
genesis. In RA, inflammation leads to excessive remodelling and tissue turnover. Tissue
destruction of the ECM in RA is mediated by enzymatic cleavage predominantly by matrix
metalloproteinases (MMPs). MMPs have been shown to be highly up-regulated in RA [11,12].
Consequently, a range of protein-degradation products are generated, which results in the
exposure of de novo sites of these fragmented proteins, referred to as neo-epitopes [13]. More-
over, these protein-degradation products may be specific for the tissue of origin and for the
involved enzymes, and may therefore be used as diagnostic and prognostic biomarkers [14].
Such biomarkers include C1M, which is a product of MMP-cleavage of type I collagen and a
biomarker of soft tissue destruction [15]. This biomarker has proved its value in RA as it is able
to depict fast progressors from slow progressing disease in the phase III tocilizumab trial
LITHE [15]. C1M in combination with MMP3 and CRPM were able to predict, which patients
had an increased chance of responding to treatment in the LITHE study [16]. CRPM is the
MMP-depended degradation product of C-reactive protein (CRP) [17]. Other soluble bio-
markers of interest include C2M, C3M, and VICM. C2M is a serum biomarker that measures a
MMP-generated neo-epitope of type II collagen, thereby reflecting cartilage degradation [18].
C3M is a biomarker of soft tissue turnover associated with inflammation [19,20], and VICM
evaluates citrullinated and MMP-degraded vimentin [21].
Since all of the mentioned biomarkers have proved useful in evaluation and characterization
of established RA [15,16] the objective of this study was to evaluate and characterize the tissue
turnover of the joints as reflected by C1M, C2M, C3M, VICM, and CRPM in early arthritis
patients. Furthermore, we studied whether these biomarkers could provide additional informa-
tion for the diagnostic and/or prognostic process in the very early phase of inflammatory
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arthritis, when peripheral blood samples are collected during the patient’s first visit to the rheu-
matology department.
Materials and Methods
Patients
Ninety-two early arthritis patients were enrolled in the prospective early arthritis ‘Synoviomics’
cohort at the Academic Medical Center (AMC) in Amsterdam between April 2004 and January
2013 in this study [22]. At baseline the selected patients either fulfilled the ACR/EULAR 2010
criteria for RA classification (n = 60) [23] or had unclassified arthritis (UA) that did not fulfill
classification criteria of established rheumatic disease (n = 33) (phase e according to the
EULAR Study Group for Risk Factors for Rheumatoid Arthritis) [24]. All patients enrolled in
the study had less than 1 year disease duration, as measured from the first clinical evidence of
joint swelling. Patients had active arthritis in at least one joint and were disease-modifying anti-
rheumatic drug (DMARD) naïve. All patients provided written informed consent. The study
was performed according to the Declaration of Helsinki and approved by the Medical Ethics
Committee of the Academic Medical Center (AMC).
Study design
At baseline, demographic data were collected and the following clinical and laboratory parame-
ters were obtained: serum levels of C-reactive protein (CRP); erythrocyte sedimentation rate
(ESR); 68 tender and 66 swollen joint count (TJC68 and SJC66); Disease Activity Score in 28
joints (DAS28); IgM-RF levels using IgM-RF ELISA (Sanquin, Amsterdam, the Netherlands
(upper limit of normal (ULN) 12.5 IU/ml)) until December 2009 and thereafter using IgM-RF
ELISA (Hycor Biomedical, Indianapolis, IN (ULN 49 IU/ml)); anti-citrullinated protein anti-
bodies (ACPA) using anti-citrullinated cyclic peptide (CCP)2 ELISA CCPlus (Eurodiagnostica,
Nijmegen, the Netherlands (ULN 25 kAU/l)); and radiographs of hands and feet.
Patients were followed for 2 years and those with UA were categorized for diagnostic out-
come as having either converted to RA (UA-RA; n = 6) or remained unclassified (UA-UA;
n = 23). Three patients were not available for follow-up, and were therefore excluded from the
diagnostic outcome analysis. Patients fulfilling the ACR/EULAR 2010 criteria for RA after 2
years follow-up were further classified for prognostic outcome into: (1) non-erosive disease
(n = 25), or (2)erosive disease (n = 13), defined as presence of joint erosions on radiographs of
the hands and/or feet [25]. The group of non-erosive disease consisted of patients with self-lim-
iting disease (n = 3), and persistent non-erosive disease (n = 22). Self-limiting disease was
defined as no arthritis on examination and no use of DMARDs or steroids in the preceding
three months. Persistent disease was defined as the presence of arthritis in at least 1 joint and/
or DMARDs or steroids use in the preceding three months but who had no evidence of joint
erosion. The prognostic outcome data were not available for 28 of the patients and were there-
fore excluded from the prognostic outcome analysis. Finally, patients were classified as being in
remission (DAS< 2.6) or not (DAS2.6) [26].
Biomarker measurements
Levels of five protein biomarkers (MMP degraded type I collagen [C1M], cartilage degradation
[C2M], MMP degraded type III collagen [C3M], citrullinated and degraded vimentin [VICM],
and MMP-degraded CRP [CRPM]) were measured in baseline patient serum samples. Mea-
surements were performed manually on blinded samples using competitive enzyme-linked
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immune sorbent assays (ELISAs) developed and produced by Nordic Bioscience (Herlev,
Denmark).
Briefly, for C1M; 96-well streptavidin plates (Roche Diagnostics, Mannheim, Germany) were
coated with biotinylated synthetic peptide Biotin-K-GSPGKDGVRG dissolved in assay buffer
(50 mM Tris, 1% BSA, 0.1% Tween-20, pH 7.4) adjusted and incubated 30 min at 20°C. 20 μL of
peptide calibrator or sample were added to appropriate wells, followed by 100 μL of conjugated
monoclonal antibody 4D3-HRP and incubated 1 hour at 20°C. Finally, 100 μL/well tetramethyl-
benzinidine (TMB) (Kem-En-Tec cat. no. 438OH) was added and the plates were incubated 15
min at 20°C in the dark. When C2Mwas measured; 4 ng/mL of biotin-KPPGRDGAAG (Ameri-
can peptide, Sunnyvale, CA) was coated onto the streptavidin pre-coated 96-well plates (Roche
Diagnostics, Mannheim, Germany) and left for 30 min at 20°C. The calibrators, controls, and
undiluted serum samples were added followed by peroxidase-conjugated monoclonal antibody
NB44-3C1, and incubated at 4°C for 20 hours. The peroxidase reaction was visualized by 15
min incubation with 3,30,5,50-tetramethylbenzidine (TMB, Kem-En-tec, Taestrup, Denmark) at
20°C. For C3M, 96-well streptavidin-coated plates (Roche Diagnostics, Mannheim, Germany)
were coated with 0.4 ng/mL of KNGETGPQGP-biotin and left for 30 min at 20°C. Calibrators,
controls, and serum samples (diluted 1:1 in incubation buffer) were added, followed by peroxi-
dase-conjugated antibody NB51-G12. The sample—antibody mix was incubated at 20°C for 60
min. TMB was added afterwards and incubated at 20°C and stopped after 15 min. CRPMmea-
surement followed the same procedure as C3M; however, applying a different peroxidase-conju-
gated antibody (NB94-1A7) and coater (KAFVFPKESDK-biotin). For measurement of serum,
VICM samples were prediluted 4 times in incubation buffer. Streptavidin-coated 96-well plates
were coated with 100 μL biotin—RLRSSVPGV—citrulline and left for 30 min at 20°C. The cali-
brators, controls, and prediluted serum samples were added followed by 100 μL of peroxidase-
conjugated monoclonal antibody NB212-1C5 and incubated at 4°C for 20 hours. Afterwards
sample/calibrator incubation 100 μL of TMB was added and plates were incubated at 20°C for
15 min. All of the mentioned incubation steps included shaking at 300 rpm. After each incuba-
tion step the plate was washed five times in washing buffer (20 mM Tris, 50 mMNaCl, pH 7.2).
The TMB reaction was stopped by adding 100 μL of stopping solution (0.1M sulfuric acid) and
measured at 450 nm with 650 nm as the reference. Calibration curves were plotted using a
4-parametric mathematical fit model.
Statistical analysis
Categorical data were depicted as number (%) and differences between study groups analyzed
using Chi-square test. Not normally distributed variables were depicted as median (interquar-
tile range, IQR). To compare baseline characteristics and biomarker concentration between the
different classification groups, the Kruskal-Wallis test was used when more than 2 groups were
compared: subsequently the Mann-Whitney U test was used to compare differences between
two subgroups. Bivariate correlations of not normally distributed variables were analyzed using
Spearman’s rank correlation test. In order to assess the discriminating power of the biomarkers
studied we generated ROC curves by using baseline diagnosis (UA or RA), by using diagnostic
outcome of the UA patients only (UA-RA or UA-UA), by mean of prognostic outcome (non-
erosive or erosive disease) and by classifying patients into remission or not as outcomes. To
examine the relationship between the biomarkers and baseline diagnosis, diagnostic outcome,
and prognostic outcome, we performed binary logistic regression. All statistical analyses were
performed by using SPSS v20.0 software (IBM Corp., Armonk, NY) and MedCalc version
14.8.1 (MedCalc Software bvba, Ostend, Belgium). A p-value of<0.05 was considered statisti-
cally significant. Bonferroni correction was applied to correct for multiple comparisons.
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Results
Early arthritis patients
Baseline characteristics of the early arthritis patients are shown in Table 1.
Age and gender were comparable between the RA and UA patients. IgM-RF positivity and
ACPA positivity were lower in the UA group compared to the RA group. Baseline ESR and
CRP were comparable between the groups, whereas DAS28 and ACPA positivity were higher
in the RA group. A schematic overview of the study is presented in Fig 1.
Baseline biomarker concentrations are higher in RA patients compared
to UA patients
We observed a significantly higher concentration of, C3M and CRPM in RA compared to UA
based on the diagnosis at baseline (p<0.001 and p = 0.004, respectively). In patients diagnosed
with RA, the median (IQR) baseline concentrations of C3M, and CRPM were 34.1 ng/mL
(24.5–41.2) and 12.8 ng/mL (9.2–16.0), respectively. For UA diagnosis at baseline, the median
(IQR) concentration of C3M and CRPM were, 23.7 ng/mL (21.5–29.4) and 9.6 ng/mL (7.6–
12.4.), respectively. C1M had a tendency to be higher in patients diagnosed with RA with a
median (IQR) level of 37.7ng/ml (26–64.1) compared to patients with UA with the median
level of 27.7ng/ml (20.4–51.3) (p = 0.028). There was no difference in concentrations of C2M
or VICM between the RA and UA diagnosis at baseline (p = 0.84 and p = 0.13, respectively).
The analysis was followed by the investigation of the biomarkers in relationship to diagnostic
outcome. After 2 years follow-up period, 6 (18%) of the patients initially classified as UA ful-
filled the classification criteria for RA. The patients were stratified in one of following three
groups considering their baseline and 2 years follow-up diagnosis: UA-UA (n = 23), UA-RA
(n = 6) (three UA patients were lost to follow-up) and RA-RA (n = 60). C3M levels was signifi-
cantly different between the groups (p = 0.005). C3M concentrations (median (IQR)) were
higher in RA-RA (34.1 ng/mL (24.6–41.2)) compared to UA-RA (23.9 ng/mL (20.40–31.9))
and UA-UA (24.1 ng/mL (21.6–29.6)). CRPM concentrations was also higher RA-RA (12.8 ng/
mL (9.2–16.0)) than in UA-UA (9.6 ng/mL (7.6–12.0)) and UA-RA (10.8 ng/mL (7.2–14.8)).
There was no statistically significant difference in concentrations of C1M, C2M and VICM
between the different diagnostic outcome groups (p = 0.16, p = 0.90 and p = 0.23, respectively).
Table 1. Baseline characteristics of early arthritis patients.
Rheumatoid arthritis Unclassiﬁed arthritis p Value
Characteristic N = 60 N = 32
Sex, female (n (%)) 42 (70) 17 (53) 0.11
Age, years (mean (SD)) 53 (40–61) 46 (34–59) 0.097
IgM-RF positive (n (%)) 35 (58) 1 (3) <0.001
ACPA positive (n (%)) 44 (73) 3 (9) <0.001
IgM-RF and ACPA bothpositive (n (%)) 30 (50) 0 <0.001
ESR, mm/hr (median (IQR)) 17 (7–37) 9 (5–22) 0.079
CRP, mg/L (median (IQR)) 6.4 (1.6–16.1) 3.0 (1.2–7.9) 0.12
DAS28 (median (IQR)) 4.7 (3.3–6.1) 3.4 (2.6–4.5) <0.001
Parameters are described as number (n (%)), mean (standard deviation) or median (interquartile range) as appropriate. IgM-RF = immunoglobulin M
rheumatoid factor; ACPA = anti-citrullinated protein antibodies; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; DAS28 = disease activity
score in 28 joints. Signiﬁcance levels were set to p<0. 0056 when corrected for multiplicity.
doi:10.1371/journal.pone.0149329.t001
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Diagnostic power of biomarkers to discriminate between RA and UA
diagnosis
To evaluate the diagnostic power of the biomarkers of joint destruction and inflammation and
of other disease activity markers to discriminate between the UA and RA groups regarding
baseline diagnosis, we calculated the area under the receiver operating characteristic
(AUROC). The diagnostic power of C1M, C3M and CRPM was highly significant with an
AUROC of 0.64 (95% CI 0.52 to 0.76), 0.73 (95% CI 0.62 to 0.84) and 0.68 (95% CI 0.57 to
0.80), respectively (Table 2). The same evaluation was performed with CCP and the disease
activity parameter DAS28 resulted in AUROC values of 0.85 (95% CI 0.762 to 0.914) and 0.74
(95% CI 0.64 to 0.84) respectively. C2M, VICM, CRP and ESR were not sufficient to reach sta-
tistical significance.
An univariate logistic analysis was used to assess the relationship between C1M, C2M,
C3M, VICM, CRPM, ESR, CRP, DAS28, RF positivity and ACPA positivity, on one hand, and
baseline diagnosis on the other. C3M was related to baseline diagnosis (OR 1.07, 95% CI 1.02
to 1.13, p = 0.006), and there was an association between CRPM and baseline diagnosis (OR
1.78, 95% CI 1.14 to 2.77, p = 0.012). Evaluated clinical parameters were significantly associ-
ated with baseline diagnosis: DAS28 (OR 1.94, 95% CI 1.34 to 2.80, p<0.001), RF positivity
(OR 43.4, 95% CI 5.6 to 340, p<0.001), and ACPA positivity (OR 26.6, 95% CI 7.1 to 99.4,
p<0.001).
Fig 1. Schematic overview of the study. At baseline the selected patients either fulfilled the ACR/EULAR
2010 criteria for the classification of rheumatoid arthritis (RA; n = 60) or had unclassified arthritis (UA; n = 32).
Patients were followed for 2 years and those with UA were categorized as having either converted to RA
(UA-RA; n = 6) or remained unclassified (UA-UA; n = 23). Patients fulfilling the ACR/EULAR 2010 criteria for
RA after the 2 years follow-up were further classified for arthritis outcome into non-erosive disease (n = 25) or
erosive disease (n = 13). * Three patients were not available for follow-up and were therefore excluded from
the diagnostic outcome analysis. **Of 28 patients the arthritis outcome data were not available and were
therefore excluded from the prognostic outcome analysis.
doi:10.1371/journal.pone.0149329.g001
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Next, we performed multivariate logistic regression analysis with C3M and CRPM in com-
bination with RF positivity, ACPA positivity and/or DAS28. C3M and CRPM did not reach
statistical significance in this analysis.
We also calculated the AUROC to assess the ability of the biomarkers to discriminate
between patients who subsequently progressed from UA to RA after 2 years and patients who
remained UA after 2 years. None of the soluble biomarkers could statistically significantly pre-
dict whether patients would be in the UA-RA group compared to the UA-UA group (Table 3).
Diagnostic power of biomarkers to discriminate between non-erosive
and erosive disease after 2 years follow-up
Prognostic outcome after 2 years follow-up was assessed in 66 patients with RA. 28 (42%)
patients could not be classified due to missing data. There were no significant differences in
baseline characteristics (including age, DAS28, sex or CRP) between the remaining patients
and those that were lost to follow-up. Among the remaining RA patients two years after initia-
tion of the study, 25 (38%) had non-erosive disease and 13 (20%) had erosive disease; Baseline
C2M concentrations were slightly higher in patients with erosive disease (0.23 ng/mL (0.19–
0.26)) compared to patients with non-erosive disease (0.18 ng/mL (0.15–0.22) as a prognostic
outcome (p = 0.011), this difference was borderline significant when adjusted for multiple
Table 2. Area under the receiver operating characteristic (AUROC) for discriminating between RA and UA baseline diagnosis.
Biomarker AUROC Std. Error 95% conﬁdence interval P value
C1M 0.64 0.062 0.52 to 0.77 0.028
C2M 0.51 0.065 0.39 to 0.64 0.838
C3M 0.73 0.055 0.62 to 0.84 <0.001
VICM 0.60 0.061 0.48 to 0.72 0.130
CRPM 0.68 0.057 0.57 to 0.80 0.004
ESR 0.61 0.060 0.49 to 0.73 0.080
CRP 0.60 0.062 0.48 to 0.72 0.117
DAS28 0.74 0.052 0.64 to 0.84 <0.001
CCP 0.85 0.039 0.76 to 0.91 <0.001
Signiﬁcance levels were set to p<0. 0056 when corrected for multiplicity.
doi:10.1371/journal.pone.0149329.t002
Table 3. Area under the receiver operating characteristic (AUROC) for discriminating between UA patients that progress to RA after 2 years of fol-
low-up and those that remain UA after 2 years of follow-up.
Biomarker AUROC Std. Error 95% conﬁdence interval P value
C1M 0.49 0.12 0.24 to 0.73 0.91
C2M 0.52 0.13 0.26 to 0.79 0.87
C3M 0.49 0.13 0.23 to 0.76 0.96
VICM 0.32 0.12 0.09 to 0.55 0.18
CRPM 0.45 0.14 0.17 to 0.73 0.71
ESR 0.68 0.14 0.41 to 0.94 0.19
CRP 0.61 0.15 0.32 to 0.90 0.42
DAS 28 0.37 0.17 0.04 to 0.70 0.33
CCP 0.53 0.14 0.34 to 0.72 0.82
Signiﬁcance levels were set to p<0. 0056 when corrected for multiplicity.
doi:10.1371/journal.pone.0149329.t003
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testing, with the highest (median (IQR)) concentration in the erosive group and the lowest con-
centration in the non-erosive group. Baseline C1M, C3M, VICM and CRPM were comparable
between the prognostic outcome groups.
This analysis was followed by the investigation of the power of the biomarkers to discrimi-
nate between groups with different prognostic outcome. The prognostic power of C2M had an
AUROC of 0.75 (95% CI 0.60 to 0.91) (Table 4). Baseline C1M, C3M, VICM, CRPM or any of
the standard clinical parameters ESR, CRP, CCP, and DAS28 were not statistically significant
predictors of outcome in this study.
Next, univariate logistic analysis was applied to assess the relationship between C1M, C2M,
C3M, VICM, CRPM, ESR, CRP, DAS28, RF positivity and ACPA positivity on the one hand
and prognostic outcome on the other. None of the markers reached statistical significance
using this approach.
Biomarker concentrations correlate significantly with clinical disease
activity measurements
The correlations between the biomarkers of joint destruction and inflammation and measures
of clinical disease activity were assessed in the overall population and separately (Table 5) in
the patients diagnosed with RA at baseline (Table 6). All soluble biomarkers tested showed sta-
tistically significant correlations with measures of disease activity.
C1M and C3M can discriminate between patients in remission and those
with persistent disease activity
Next, we investigated the power of the biomarkers to discriminate between patients in remis-
sion (DAS<2.6) versus those with active disease. First, we evaluated the power of C1M and
C3M to discriminate between remission versus active disease in UA and RA patients (n = 10
patients in remission; n = 82 patients with active disease) and found that these were significant
with an AUROC of 0.75 (95% CI 0.62 to 0.88) and 0.79 (95% CI 0.68 to 0.89), respectively.
C2M, VICM, CRPM did not appear to provide any information in this regard. Secondly, we
performed this analysis in RA patients only (n = 3 patients in remission; n = 57 patients with
active disease) and found that C1M, C3M and CRPM were significant with an AUROC of 0.84
(95% CI 0.68 to 1.00), 0.94 (95% CI 0.87 to 1.00), and 0.91 (95% CI 0.80 to 1.00), respectively.
Table 4. Area under the receiver operating characteristic (AUROC).
Biomarker AUROC Std. Error 95% conﬁdence interval P value
C1M 0.51 0.11 0.3 to 0.71 0.96
C2M 0.75 0.08 0.60 to 0.91 0.01
C3M 0.51 0.11 0.30 to 0.73 0.89
VICM 0.57 0.10 0.38 to 0.76 0.50
CRPM 0.57 0.11 0.36 to 0.79 0.47
ESR 0.51 0.10 0.31 to 0.71 0.93
CRP 0.59 0.10 0.40 to 0.78 0.38
DAS28 0.46 0.10 0.27 to 0.66 0.70
CCP 0.62 0.09 0.49–0.73 0.18
AUROCs discriminating between non-erosive and erosive disease for patients fulﬁlling the RA criteria after 2 years of follow-up. Signiﬁcance levels were
set to p<0. 0056 when corrected for multiplicity.
doi:10.1371/journal.pone.0149329.t004
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Discussion
This early arthritis study investigated five neo-epitopes (C1M, C2M, C3M, VICM, CRPM),
which are soluble biomarkers each representing different aspects of joint destruction and inflam-
mation. We aimed to determine the ability of these biomarkers to improve the current diagnostic
and/or prognostic process in early arthritis patients and to investigate the tissue turnover in the
joints reflected by these biomarkers in early arthritis patients. The applied biomarkers evaluate
neo-epitopes released during tissue turnover, and they are therefore sensitive measures of alter-
ations during pathological events in inflamed tissue. We investigated the biomarker profile in
early RA as well as in early UA patients. We demonstrated that early RA is associated with signif-
icantly increased serum levels of C3M and CRPM hence increased connective tissue turnover
Table 5. Correlations between baseline biomarker concentration and other parameters for disease activity in the overall population (UA+RA).
DAS28 ESR CRP SJC66 TJC68 HAQ
C1M p <0.001 <0.001 <0.001 0.003 0.040 0.004
r 0.53 0.66 0.87 0.31 0.21 0.30
C2M p 0.15 0.029 0.067 0.22 0.93 0.34
r 0.15 0.23 0.19 0.13 -0.010 -0.10
C3M p <0.001 <0.001 <0.001 0.001 0.009 0.14
r 0.63 0.73 0.65 0.34 0.27 0.16
VICM p 0.019 0.13 0.015 0.039 0.047 0.11
r 0.25 0.16 0.25 0.22 0.21 0.17
CRPM p <0.001 <0.001 <0.001 0.003 0.10 0.12
r 0.47 0.60 0.60 0.31 0.17 0.28
The correlations between the biomarkers of joint destruction and inﬂammation and measures of clinical disease activity were assessed in the overall
population (UA+RA) at baseline. UA = unclassiﬁed arthritis; RA = rheumatoid arthritis; DAS28 = disease activity score in 28 joints; ESR = erythrocyte
sedimentation rate; CRP = C-reactive protein; SJC66 = 66 swollen joint score; TJC68 = 68 tender joint score; HAQ = health assessment questionnaire;
C1M = matrix metalloproteinases (MMP) degraded type I collagen; C2M = MMP degraded type II collagen; C3M = MMP degraded type III collagen;
VICM = citrullinated and degraded vimentin; CRPM = MMP degraded CRP. Signiﬁcance levels were set to p<0.01 when corrected for multiplicity.
doi:10.1371/journal.pone.0149329.t005
Table 6. Correlations between baseline biomarker concentration and other parameters for disease activity in the population with RA.
DAS28 ESR CRP SJC66 TJC68 HAQ
C1M p <0.001 <0.001 <0.001 0.007 0.16 0.003;
r 0.57 0.69 0.89 0.35 0.18 0.38
C2M p 0.024 0.026 0.079 0.19 0.45 0.88
r 0.29 0.29 0.23 0.19 0.10 0.02
C3M p <0.001 <0.001 <0.001 0.004 0.12 0.15
r 0.60 0.69 0.66 0.37 0.20 0.19
VICM p 0.15 0.35 0.27 0.37 0.59 0.15
r 0.19 0.12 0.15 0.12 0.07 0.19
CRPM p <0.001 <0.001 <0.001 0.010 0.28 0.13
r 0.48 0.58 0.58 0.33 0.14 0.20
The correlations between the biomarkers of joint destruction and inﬂammation and measures of clinical disease activity in the patients diagnosed with RA
at baseline. RA = rheumatoid arthritis; DAS28 = disease activity score in 28 joints; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein;
SJC66 = 66 swollen joint score; TJC68 = 68 tender joint score; HAQ = health assessment questionnaire; C1M = matrix metalloproteinases (MMP)
degraded type I collagen; C2M = MMP degraded type II collagen; C3M = MMP degraded type III collagen; VICM = citrullinated and degraded vimentin;
CRPM = MMP degraded CRP. Signiﬁcance levels were set to p<0. 01 when corrected for multiplicity.
doi:10.1371/journal.pone.0149329.t006
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compared to UA. Also C1M levels appeared to be increased in RA compared to UA although
this tendency was not significant after Bonferroni correction for multiple testing. Furthermore,
our results indicates that turnover of cartilage, reflected by C2M, levels was elevated in early RA
patients who subsequently developed erosive disease after 2 years of follow-up.
The diagnostic utility of the biomarkers was explored in early RA patients and we found
that the biomarkers C1M, C3M and CRPM all had a diagnostic power which was comparable
to the standard disease parameter DAS28 when evaluated as AUROC. This is not unexpected
since RA is characterized by massive changes of metabolic processes in the joints, which
includes cartilage degradation and connective tissue turnover as a consequence of synovial
inflammation. Thus C1M, C3M and CRPM add further information to the well-established
clinical parameters. However the diagnostic power of CCP was exceeding all of the evaluated
biomarkers as well as DAS28 with an AUROC value of 0.85. All of the applied biomarkers cor-
related with one or more of the established parameters for disease activity, such as DAS28,
ESR, and/or CRP. These results presented here support the notion that connective tissue degra-
dation relates to the inflammatory process in RA. However, the soluble biomarkers tested were
unable to predict which of the UA patients at baseline would eventually fulfil classification cri-
teria for RA since the levels of soluble biomarkers were not statistically significantly different
between the UA-RA group and the UA-UA group. Single use of a biomarker may therefore not
provide enough diagnostic information since RA is a very heterogeneous disease.
Type I, II and III collagen are the main collagens in the joint. Therefore, an increase in
MMP fragments of these collagens may provide novel information about connective tissue bal-
ance. Indeed, earlier studies demonstrated an association between elevated levels of serum
C2M and severity of osteoarthritis, suggesting that C2M could be applied as a biomarker for
cartilage loss or degradation [27]. This is in line with our study, which indicated that C2M con-
centrations were different between the prognostic outcome groups, with a tendency of higher
concentrations in erosive disease.
These findings suggest that the biomarkers may contribute with independent and additive
information about the disease pathogenesis and may provide supplementary diagnostic tools for
clinical diagnosis. These biomarkers should not compete with current diagnostic tools for clini-
cal diagnosis or disease activity. Instead they provide additional information on tissue integrity.
A limitation of this study is the relatively small sample size; there was a limited number of
UA-RA patients (n = 6). Larger studies including higher numbers of early arthritis patients fol-
lowed longitudinally are needed to confirm these initial findings. In addition it would be pref-
erable to include healthy and age matched non-arthritic patients for the comparison.
This study shows for the first time that measurement of C1M, C3M, and CRPMmay assist
in differential diagnosis in early arthritis patients. In addition, C2M might be a prognostic bio-
marker predictive of the development of erosive disease. The results provide the rationale for
larger studies in early arthritis patients to confirm and extend these findings.
Raw data of demographics and clinical and laboratory parameters as well as biomarker mea-
surements underlying the presented findings are available in the S1 Dataset.
Supporting Information
S1 Dataset.
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